No Data
No Data
No Data
No Data
No Data
Kangtai Biotech (300601): Sales revenue of conventional vaccines increased 19% year-on-year, and commercialization of human diploid rabies vaccine is being promoted
Revenue from routine vaccine sales increased 19% year over year. In 2023, the company achieved revenue of 3.477 billion yuan (year-on-year +10.1%), and sales revenue of 3,505 billion yuan (year-on-year +19) for conventional vaccines (excluding COVID-19 vaccines)
國信證券42minutes ago
Kangtai Biotech (300601): The performance is basically in line with expectations, and the release of new products can be expected
Key investment results are generally in line with expectations. In 2023, the company achieved operating income of 3.477 billion yuan (+10.14%), net profit to mother of 861 million yuan (+749.02%), and net profit of non-return to mother of 722 million yuan (
東海證券Apr 30 00:00
Kangtai Biotech (300601): Regular vaccines are growing steadily, and new product releases are expected
Incident: The company released its 2023 annual report, achieving operating income of 3.48 billion yuan, an increase of 10.1% over the previous year; realized net profit attributable to shareholders of the parent company of 860 million yuan (+749%); realized net profit of 720 million yuan after deduction
西南證券Apr 28 00:00
Express News | Kangtai Biotech: Net profit due to mother in 2023 was 861 million yuan, an increase of 749.02% year-on-year
BreakingsApr 26 19:19
Express News | Kangtai Biotech: Live attenuated chickenpox vaccine obtained drug registration certificate
BreakingsApr 16 18:35
Express News | Kangtai Biotech: Sabin Polio Inactivated Vaccine (Vero Cell) Application for Production Registration Accepted
BreakingsApr 11 20:23
No Data
No Data